Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep as a potential bispecific or ADC payload.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 05, 2023 9:49am

171 Views

Post# 35768755

RE:RE:RE:RE:ONCY pelareorep as a potential bispecific or ADC payload.

AbbVie plans to acquire ImmunoGen for $10.1 Billion, in a deal that would expand the Big Pharma’s presence in the oncology field and mark an exit for the 42-year-old Boston biotech. ImmunoGen was founded in 1981.

In early 2000 Pfizer was the first to introduce an ADC which turned into the developing plan to acquire ADC company Seagen for US$ 43 Billion.

I guess that both Immunogen and Seagen had a dream that finally came to fruition.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity